Document Detail


Fatty heart, cardiac damage, and inflammation.
MedLine Citation:
PMID:  22262077     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Type 2 diabetes and obesity are associated with systemic inflammation, generalized enlargement of fat depots, and uncontrolled release of fatty acids (FA) into the circulation. These features support the occurrence of cardiac adiposity, which is characterized by an increase in intramyocardial triglyceride content and an enlargement of the volume of fat surrounding the heart and vessels. Both events may initially serve as protective mechanisms to portion energy, but their excessive expansion can lead to myocardial damage and heart disease. FA overload promotes FA oxidation and the accumulation of triglycerides and metabolic intermediates, which can impair calcium signaling, β-oxidation, and glucose utilization. This leads to damaged mitochondrial function and increased production of reactive oxygen species, pro-apoptotic, and inflammatory molecules, and finally to myocardial inflammation and dysfunction. Triglyceride accumulation is associated with left ventricular hypertrophy and dysfunction. The enlargement of epicardial fat in patients with metabolic disorders, and coronary artery disease, is associated with the release of proinflammatory and proatherogenic cytokines to the subtending tissues. In this review, we examine the evidence supporting a causal relationship linking FA overload and cardiac dysfunction. Also, we disentangle the separate roles of FA oxidation and triglyceride accumulation in causing cardiac damage. Finally, we focus on the mechanisms of inflammation development in the fatty heart, before summarizing the available evidence in humans. Current literature confirms the dual (protective and detrimental) role of cardiac fat, and suggests prospective studies to establish the pathogenetic (when and how) and possible prognostic value of this potential biomarker in humans.
Authors:
Maria A Guzzardi; Patricia Iozzo
Related Documents :
2318227 - Hypertrophic cardiomyopathy: is a left ventricular outflow tract gradient a major progn...
15235057 - 123i-mibg myocardial scintigraphy in patients with "takotsubo" cardiomyopathy.
21183727 - Failure of the adipocytokine, resistin, to protect the heart from ischemia-reperfusion ...
16733507 - Peripartum cardiomyopathy.
17697027 - Detection of left ventricular dysfunction by doppler tissue imaging in patients with co...
6277567 - 99mtc-labelled pyrophosphate myocardial scanning in experiment and in clinical practice.
Publication Detail:
Type:  Journal Article; Review     Date:  2011-11-10
Journal Detail:
Title:  The review of diabetic studies : RDS     Volume:  8     ISSN:  1614-0575     ISO Abbreviation:  Rev Diabet Stud     Publication Date:  2011  
Date Detail:
Created Date:  2012-01-20     Completed Date:  2012-06-28     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  101227575     Medline TA:  Rev Diabet Stud     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  403-17     Citation Subset:  IM    
Copyright Information:
Copyright © by Lab & Life Press/SBDR
Affiliation:
Institute of Clinical Physiology, National Research Council (CNR), Via Moruzzi 1, 56124 Pisa, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adiposity
Animals
Diabetes Mellitus, Type 2 / complications*,  drug therapy
Fatty Acids / metabolism*
Heart / drug effects,  physiopathology
Heart Diseases / etiology,  immunology*,  metabolism,  physiopathology
Humans
Hypoglycemic Agents / therapeutic use
Triglycerides / metabolism*
Chemical
Reg. No./Substance:
0/Fatty Acids; 0/Hypoglycemic Agents; 0/Triglycerides
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The kidney in type 2 diabetes therapy.
Next Document:  GLP-1, the gut-brain, and brain-periphery axes.